Dendritic cells in patients with non-progressive B-chronic lymphocytic leukaemia have a normal functional capability but abnormal cytokine pattern

British Journal of Haematology

Volumn 115, Issue 2, 2001, Pages 263-271

  Reza Rezvany, Mohammad ^a   Jeddi Tehrani, Mahmood ^a   Biberfeld, Peter ^a   Söderlund, Johan ^a   Mellstedt, Håkan ^a   Österborg, Anders ^a   Rabbani, Hodjattallah ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CLL; Cytokines; Dendritic cells; Functional activity; Non progressive disease

Indexed keywords

B7 ANTIGEN; CD123 ANTIGEN; CD14 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GLYCOPROTEIN P 15095; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACCESSORY CELL; AGED; ARTICLE; CELL POPULATION; CHEMICAL ANALYSIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; FLUORESCENCE; GENE EXPRESSION; HISTOCOMPATIBILITY COMPLEX; HUMAN; HUMAN CELL CULTURE; IN VIVO STUDY; MALE; PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; SURFACE PROPERTY; VACCINATION;

AGED; ANTIGEN PRESENTATION; ANTIGENS, CD14; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CYTOKINES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, B-CELL, CHRONIC; LYMPHOCYTE CULTURE TEST, MIXED; MALE; POLYMERASE CHAIN REACTION; T-LYMPHOCYTES;

EID: 0035726552     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.03117.x     Document Type: Article

References (55)

1. Cytokine expression in B-CLL in relation to disease progression and in vitro activation
2. Advances in the biology of multiple myeloma: Therapeutic applications
3. Generation of dendritic cells from peripheral blood adherent cells in medium with human serum
4. Immunobiology of dendritic cells
5. Dendritic cells and the control of immunity
6. Separation of lymphocytes, lymphocyte subgroups and monocytes: A review
7. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1
8. Pathways of development of human dendritic cells
9. CD341+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis
10. Origin, maturation and antigen presenting function of dendritic cells
11. Differentiation of human dendritic cells from monocytes in vitro
12. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 constimulatory molecules of the T-cell activation
13. Single-step method of RNA isoltion by acid guanidinum thiocyanate-phenol-chloroform extraction
14. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses
15. The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation
16. Dendritic cells directly modulate B cell growth and differentiation
17. An essential role for Langerhans cell-derived IL-1 beta in the initiation of primary immune responses in skin
18. T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma
19. Real-time quantitative RT-PCR after laser-assisted cell picking
20. Interleukin 10 induces apoptotic cell death of B-chronic lymphocytic leukaemia cells
21. Dendritic cells in cancer immunotherapy
22. Decreased antigen presentation by dendritic cells in patients with breast cancer
23. Secretion of bioactive interleukin-1beta by dendritic cells is modulated by interaction with antigen specific T cells
24. The function of costimulatory molecules and the development of IL-4- producing T cells
25. A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state
26. Real time quantitative PCR
27. Generation of dendritic cells from patients with chronic myelogenous leukemia
28. Vaccination of patients with B-cell lymphoma using autologous antigen- pulsed dendritic cells
29. Treatment of chronic lymphocytic leukaemia and well-differentiated lymphocytic lymphoma with continuous low- or intermittent high-dose prednimustine versus chlorambucil/prednisolone
30. Characterization of interleukin-10 receptor expression on B-cell chronic lymphocytic leukemia cells
31. Kinetic of dendritic cell activation: Impact on priming of Th1, Th2 and nonpolarized T cells
32. Dendritic cells in B-CLL chronic lymphocytic leukemia are neoplastic and may be of pluripotent stem cell origin
33. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8 (+) T cells
34. HLA-DR1-restricted bcr-abl (b3a2) -specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates
35. Phenotypic and functional characteristics of monocyte-derived dendritic cells from patients with myelodysplastic syndromes
36. Flow cytometric visualisation of cytokine production by CD3-CD56+ NK cells and CD3+CD56+NK-T cells in whole blood
37. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: Implications for live kidney cancer vaccines
38. IL-12 responsiveness and expression of IL-12 receptor in human peripheral blood monocyte-derived dendritic cells
39. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature
40. Idiotype immunization combined with granulocyte-macrophage colony- stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8+ and CD4+ specific T-cell responses
41. Dendritic cells as the terminal stage of monocyte differentiation
42. Immunological gene therapy with ex vivo gene-modified tumor cells: A critique and a reappraisal
43. Characterization of malignant and non-neoplastic cell phenotypes in highly malignant non-Hodgkin lymphomas
44. Modulating the immune response with dendritic cells and their growth factors
45. Clinical staging of chronic lymphocytic leukemia
46. Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia: Major perturbations are preferentially seen within the CD4 T-cell subset
47. Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH- CDR3 region in patients with B-cell chronic lymphocytic leukaemia
48. Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia
49. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability
50. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha
51. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy
52. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application
53. Mantle cell lymphoma proliferates upon IL-10 in the CD40 system
54. Generation of mature dendritic cells from a CD14+ cell line (XS52) by IL-4, TNF-alpha, IL-1 beta, and agonistic anti-CD40 monoclonal antibody